FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
In a challenging year for In8bio Inc, the biotechnology firm’s stock has plummeted to a 52-week low, trading at a mere $0.16. This significant downturn reflects an alarming 1-year change, with the company’s stock value eroding by -84.33%. According to InvestingPro data, the stock’s RSI indicates oversold territory, while analyst price targets range from $1.20 to $7.50, suggesting potential recovery opportunities. Investors have watched with concern as In8bio Inc, which specializes in developing cancer therapies, has struggled to maintain its market position amidst a competitive and rapidly evolving industry landscape. With a market capitalization of just $13.57 million and a current ratio of 4.08, the company maintains strong short-term liquidity despite its challenges. The 52-week low serves as a stark indicator of the hurdles the company faces, and it underscores the urgency for a strategic turnaround to regain investor confidence and market value. Unlock comprehensive valuation metrics and 11 additional expert insights with InvestingPro.
In other recent news, IN8bio has reported promising results from its Phase 1 trial for the INB-100 therapy, aimed at treating acute myeloid leukemia (AML). The trial showed a 100% relapse-free survival rate over a median follow-up of 20.1 months, with no instances of relapse among the patients treated. This outcome significantly surpasses historical control data, suggesting a potential shift in post-transplant care for AML patients. Furthermore, the company announced that the INB-100 therapy demonstrated a favorable safety profile, with no significant side effects such as cytokine release syndrome or neurotoxicity. In related developments, Jones Trading upgraded IN8bio’s stock rating to Buy, setting a new price target of $1.20, in light of the encouraging clinical outcomes. Meanwhile, H.C. Wainwright maintained its Buy rating on IN8bio but adjusted the price target from $8.00 to $6.00, following a recent capital raise by the company. Additionally, IN8bio announced the resignation of board member Travis Whitfill, effective May 9, 2025, with no disagreements cited regarding company operations. Investors and stakeholders will likely monitor these developments closely as IN8bio continues its clinical advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.